Clinical trial
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
NCT03022825 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
- Lead sponsor
- ImmunityBio, Inc.
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- June 2, 2017
- Completion date
- March 1, 2029
- Enrollment
- 190 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
bladder cancer